Comparing The Effectiveness Of Individualized Homoeopathic Medicines Vs Chrysarobinum In The Treatment Of Dermatophytosis

To Evaluate The Effectiveness Of Individualized Homoeopathic Medicines Vs Chrysarobinum For The Treatment Of Dermatophytosis: A Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093355

Enrollment

Registered

2025-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B35- Dermatophytosis

Interventions

Intervention1: Individualized Homoeopathic Medicines: Individualized Homoeopathic Medicines will be administered in centesimal potencies, selected according to homoeopathic principles. The dose and re

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient suffering from Dermatophytosis based on clinical presentation of lesions. Desirable ? evidence of presence of fungal hyphae, spores on microscopic examination on KOH wet mount. 2. Both sexes of age group 18 years to 65 years. 3. Not using any systemic/ topical antifungal treatment for past 2 weeks. 4. Patient who are willing for regular follow-ups.

Exclusion criteria

Exclusion criteria: 1. Dermatophytosis patients suffering from any life-threatening illness who are terminally ill, under immuno-suppressive treatment or self-reported immuno-compromised state. 2. Patients of malignancy or too sick for consultation. 3. Diagnosed case of mental illness / psychiatric/ other uncontrolled/ life threatening conditions. 4. Patients taking any other mode of treatment. 5. Pregnant and lactating mothers. 6. Substance abuse and or dependence

Design outcomes

Primary

Measure	Time frame
The study is expected to yield better therapeutic results with Individualized homoeopathic medicines as compared to Chrysarobinum in treatment of dermatophytosis.Timepoint: 1 year (12 months)	—

Secondary

Measure	Time frame
1. This study anticipates improvements in itching severity and quality of life among patients receiving homoeopathic medicines as reflected by improved scores on the Peak Pruritus Numeric Rating Scale and the Dermatology Life Quality Index (DLQI). 2. A reduction or clearance of fungal elements is expected to be observed on potassium hydroxide (KOH) microscopic examination following homoeopathic treatment. 3. The study is expected to highlight a subset of individualized homoeopathic medicines that are more frequently prescribed and associated with positive clinical outcomes in the management of dermatophytosis. 4. The study is expected to outline the clinical indications of Chrysarobinum- demonstrating its clinical effectiveness in treating dermatophytosis.Timepoint: 1 year (12 months)	—

Measure

Time frame

1. This study anticipates improvements in itching severity and quality of life among patients receiving homoeopathic medicines as reflected by improved scores on the Peak Pruritus Numeric Rating Scale and the Dermatology Life Quality Index (DLQI). 2. A reduction or clearance of fungal elements is expected to be observed on potassium hydroxide (KOH) microscopic examination following homoeopathic treatment. 3. The study is expected to highlight a subset of individualized homoeopathic medicines that are more frequently prescribed and associated with positive clinical outcomes in the management of dermatophytosis. 4. The study is expected to outline the clinical indications of Chrysarobinum- demonstrating its clinical effectiveness in treating dermatophytosis.Timepoint: 1 year (12 months)

—

Countries

India

Contacts

Public ContactDr Aishwarya Shukla

Dr B R Sur Homoeopathic Medical College, Hospital And Research Centre

drrajivh@yahoo.co.in7994273285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026